Richtig, dies führt jedoch nicht zum vermehrten Auftreten von Infektionskrankheiten. Mir ist jedenfalls keine Studie bekannt, die dies belegt.
:-top - Da war ich mir auch nicht sicher!
Hab gerade mal nachgeschaut und folgendes Paper von 2004 aus JAMA gefunden. Wusste ich vorher nicht und finde ich ziemlich interessant. Schaut man bei PUBMED nach, findet man noch mehr Literatur zu dem Thema. Habe von hier leider nur Zugriff auf das Abstract, aber würde gerne mal einen Blick in das komplette Paper werfen :-stud!
JAMA. 2004 Oct 27;292(16):1955-60.
Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs.
Laheij RJ, Sturkenboom MC, Hassing RJ, Dieleman J, Stricker BH, Jansen JB.
Department of Gastroenterology, University Medical Center St. Radboud, Nijmegen,
The Netherlands.
[email protected]
CONTEXT: Reduction of gastric acid secretion by acid-suppressive therapy allows
pathogen colonization from the upper gastrointestinal tract. The bacteria and
viruses in the contaminated stomach have been identified as species from the
oral cavity. OBJECTIVE: To examine the association between the use of
acid-suppressive drugs and occurrence of community-acquired pneumonia. DESIGN,
SETTING, AND PARTICIPANTS: Incident acid-suppressive drug users with at least 1
year of valid database history were identified from the Integrated Primary Care
Information database between January 1, 1995, and December 31, 2002. Incidence
rates for pneumonia were calculated for unexposed and exposed individuals. To
reduce confounding by indication, a case-control analysis was conducted nested
in a cohort of incident users of acid-suppressive drugs. Cases were all
individuals with incident pneumonia during or after stopping use of
acid-suppressive drugs. Up to 10 controls were matched to each case for
practice, year of birth, sex, and index date. Conditional logistic regression
was used to compare the risk of community-acquired pneumonia between use of
proton pump inhibitors (PPIs) and H2-receptor antagonists. MAIN OUTCOME MEASURE:
Community-acquired pneumonia defined as certain (proven by radiography or sputum
culture) or probable (clinical symptoms consistent with pneumonia). RESULTS: The
study population comprised 364,683 individuals who developed 5551 first
occurrences of pneumonia during follow-up. The incidence rates of pneumonia in
non-acid-suppressive drug users and acid-suppressive drug users were 0.6 and
2.45 per 100 person-years, respectively. The adjusted relative risk for
pneumonia among persons currently using PPIs compared with those who stopped
using PPIs was 1.89 (95% confidence interval, 1.36-2.62). Current users of
H2-receptor antagonists had a 1.63-fold increased risk of pneumonia (95%
confidence interval, 1.07-2.48) compared with those who stopped use. For current
PPI users, a significant positive dose-response relationship was observed. For
H2-receptor antagonist users, the variation in dose was restricted. CONCLUSION:
Current use of gastric acid-suppressive therapy was associated with an increasedrisk of community-acquired pneumonia.